Binbin QIAN¹, Xiaoduo LIU², Xiaolin GU¹, Lu YANG³, Dake CHEN^1,*

BIOCELL, Vol.44, No.1, pp. 19-26, 2020, DOI:10.32604/biocell.2020.07859

Abstract Prolylcarboxypeptidase (PRCP) belongs to the S28 family of proteases, which is also a dipeptidyl peptidase. In this study, we demonstrate the expression pattern of PRCP in Non-small cell lung cancer (NSCLC). We found that the repression of PRCP expression by small interfering RNA successfully inhibited cell proliferation, migration, and invasion. Further, we explored the involvement of PRCP in the regulation of epithelial-mesenchymal transition (EMT). The epithelial marker E-cadherin was significantly increased, meanwhile mesenchymal markers MUC1, vimentin, and SNAIL were markedly decreased in PRCP knockdown cells. Moreover, the downregulation of PRCP in the NSCLC cells induced the expression of apoptosis-related proteins… More >

Dairong LI¹, Xianlu ZHUO^1,2, Lumi HUANG¹, Xiaohui JI¹, Donglin WANG¹

BIOCELL, Vol.43, No.3, pp. 139-144, 2019, DOI:10.32604/biocell.2019.06460

Abstract X-ray repair cross-complementing protein 1 (XRCC1) could repair cisplatin-induced DNA damage. XRCC1 Arg399Gln and Arg194Trp variants alter XRCC1 expression and function, leading to changes in cancer sensitivity to cisplatin treatment. This study aimed to investigate the effects of XRCC1 Arg399Gln and Arg194Trp polymorphisms on cell viability, apoptosis and XRCC1 expression in cisplatin-sensitive A549 and cisplatin-resistant A549/DDP nonsmall cell lung cancer (NSCLC) cells. Plasmids carrying XRCC1 Arg399Gln and Arg194Trp were constructed and transfected into A549 and A549/DDP cells. RT–PCR, Western blot, MTT assay, and flow cytometry analysis were performed to assess cell viability, apoptosis, and XRCC1 expression. Compared to control cells,… More >